https://orcid.org/0000-0002-5189-3326
Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Lijuan Xu, Wannian Zhang & Chunlin Zhuang. (2023) Receptor-interacting protein kinase 1 (RIPK1) inhibitor: a review of the patent literature (2018-present). Expert Opinion on Therapeutic Patents 33:2, pages 101-124.
Read now
Read now
Articles from other publishers (11)
Craig E. StivalaDomagoj Vucic. 2023. 2023 Medicinal Chemistry Reviews. 2023 Medicinal Chemistry Reviews
83
102
.
Ying Qin, Dekang Li, Chunting Qi, Huaijiang Xiang, Huyan Meng, Jingli Liu, Shaoqing Zhou, Xinyu Gong, Ying Li, Guifang Xu, Rui Zu, Hang Xie, Yechun Xu, Gang Xu, Zheng Zhang, Shi Chen, Lifeng Pan, Ying Li & Li Tan. (2023) Structure-based development of potent and selective type-II kinase inhibitors of RIPK1. Acta Pharmaceutica Sinica B.
Crossref
Crossref
Hongming Shao, Lijuan Xu, Gechang Li, Shuyu Wang, Ting Han & Chunlin Zhuang. (2023) Analysis on benzothiazole necroptosis inhibitors with chiral substitutions in the solvent-accessible region of RIP kinase domain. Bioorganic Chemistry 137, pages 106647.
Crossref
Crossref
Zhong-Yi Ling, Quan-Zhen Lv, Jiao Li, Ren-Yi Lu, Lin-Lin Chen, Wei-Heng Xu, Yan Wang & Chun-Lin Zhuang. (2023) Protective Effect of a Novel RIPK1 Inhibitor, Compound 4–155, in Systemic Inflammatory Response Syndrome and Sepsis. Inflammation.
Crossref
Crossref
Lijuan Xu & Chunlin Zhuang. (2023) Profiling of small‐molecule necroptosis inhibitors based on the subpockets of kinase–ligand interactions. Medicinal Research Reviews.
Crossref
Crossref
Christopher R. Gardner, Katherine A. Davies, Ying Zhang, Martin Brzozowski, Peter E. Czabotar, James M. Murphy & Guillaume Lessene. (2023) From (Tool)Bench to Bedside: The Potential of Necroptosis Inhibitors. Journal of Medicinal Chemistry 66:4, pages 2361-2385.
Crossref
Crossref
Zhichao Li, Dandan Li, Renchang Chen, Shang Gao, Zhanwang Xu & Nianhu Li. (2023) Cell death regulation: A new way for natural products to treat osteoporosis. Pharmacological Research 187, pages 106635.
Crossref
Crossref
Kunyu Shi, Jifa Zhang, Enda Zhou, Jiaxing Wang & Yuxi Wang. (2022) Small-Molecule Receptor-Interacting Protein 1 (RIP1) Inhibitors as Therapeutic Agents for Multifaceted Diseases: Current Medicinal Chemistry Insights and Emerging Opportunities. Journal of Medicinal Chemistry 65:22, pages 14971-14999.
Crossref
Crossref
Yi Sun, Lijuan Xu, Hongming Shao, Danni Quan, Zixin Mo, Jue Wang, Wannian Zhang, Jianqiang Yu, Chunlin Zhuang & Ke Xu. (2022) Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease. Journal of Medicinal Chemistry 65:21, pages 14957-14969.
Crossref
Crossref
Wenli Zhao, Yue Liu, Lijuan Xu, Yuan He, Zhenyu Cai, Jianqiang Yu, Wannian Zhang, Chengguo Xing, Chunlin Zhuang & Zhuo Qu. (2022) Targeting Necroptosis as a Promising Therapy for Alzheimer’s Disease. ACS Chemical Neuroscience 13:12, pages 1697-1713.
Crossref
Crossref
Danuta Jantas & Władysław Lasoń. (2021) Preclinical Evidence for the Interplay between Oxidative Stress and RIP1-Dependent Cell Death in Neurodegeneration: State of the Art and Possible Therapeutic Implications. Antioxidants 10:10, pages 1518.
Crossref
Crossref